SecBot SecBot
Biotech Drug Report Generated Nov 5, 2026

RISPERDAL CONSTA

ALKS·Alkermes plc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed since 2003. No further regulatory steps pending.
Why 3/10
Risperdal Consta is already FDA-approved (2003) and has no pending regulatory decision, pivotal readout, or other hard binary catalyst scheduled. For Alkermes, it is a legacy third-party licensing/manufacturing revenue stream facing generic erosion, not a company-defining asset. ImpactScore is 3 per the rubric for an approved, marketed drug with no imminent new regulatory decision.
Actionable Insight NEUTRAL

Risperdal Consta is a mature, generic-eroding asset for Alkermes. Watch the quarterly manufacturing and royalty revenue line for continued erosion as Lupin's generic gains share. The real value drivers for ALKS are its proprietary portfolio (ARISTADA, LYBALVI, VIVITROL, LUMRYZ) and the orexin pipeline readouts expected over the next year. Risperdal Consta itself has no upcoming binary catalyst.

Price Chart

Loading chart...

Executive Summary

Risperdal Consta (risperidone long-acting injection) is an FDA-approved atypical antipsychotic for schizophrenia (approved 2003) and bipolar I disorder (approved 2009). It uses Alkermes' proprietary Medisorb microsphere technology for sustained release over two weeks. The drug is commercialized by Janssen (Johnson & Johnson), not Alkermes directly. Alkermes receives a 2.5% royalty on net sales and manufacturing revenue from producing the drug at its Wilmington, Ohio facility. A generic version from Lupin was FDA-approved in September 2025 and launched in November 2025, putting pressure on brand sales and Alkermes' related revenue. For Alkermes, Risperdal Consta is a legacy third-party revenue stream that has been declining, while the company's strategic focus is on its proprietary product portfolio (ARISTADA, LYBALVI, VIVITROL, LUMRYZ) and its orexin pipeline. There are no upcoming binary catalysts for this drug.

How It Works

Risperdal Consta is a long-acting injectable form of risperidone, an atypical antipsychotic medication. It works by balancing levels of dopamine and serotonin in the brain, which helps regulate mood, thoughts, and behaviors. The drug is encapsulated in biodegradable microspheres using Alkermes' Medisorb technology, which slowly releases the medication over two weeks after a single intramuscular injection. This eliminates the need for daily pills and helps patients maintain consistent drug levels.

Trial Status

Risperdal Consta is a commercially marketed product. It was originally approved by the FDA in 2003 for schizophrenia and received a supplemental approval in 2009 for bipolar I disorder. No new clinical trials are being conducted by Alkermes for this drug, as it is a mature product facing generic competition.

The Two-Sided Case

▲ Bull Case4
Proven technology platform: Risperdal Consta was the first long-acting atypical antipsychotic and validates Alkermes' Medisorb microsphere delivery technology, which also underpins other partnered products (INVEGA SUSTENNA, INVEGA TRINZA, VUMERITY).
Manufacturing moat: Alkermes exclusively manufactures Risperdal Consta at its Wilmington, Ohio facility for Janssen, providing a steady (if declining) manufacturing revenue stream that is not easily replaced.
Royalty upside if manufacturing stops: If Janssen terminates the manufacturing agreement without terminating the license, the royalty rate on net sales would double from 2.5% to 5.0%, partially offsetting lost manufacturing revenue.
Still a meaningful market: The Risperdal Consta market was valued at roughly $187 million (IQVIA September 2025 data for the 25/37.5/50 mg strengths), so even with generic erosion, some revenue persists.
▼ Bear Case4
Generic competition: Lupin received FDA approval for a generic version in September 2025 and launched in November 2025 with 180-day CGT exclusivity, directly undercutting brand sales and Alkermes' manufacturing/royalty revenue.
Declining revenue stream: Risperdal Consta manufacturing revenue fell $5.0 million in Q1 2026 vs prior year, and total manufacturing and royalty revenues dropped 18.1% year-over-year in Q3 2026, partly due to lumpy batch timing but also reflecting generic pressure.
Low royalty rate: Alkermes receives only a 2.5% royalty on Janssen's net sales of Risperdal Consta (rising to 5.0% only if Janssen terminates the manufacturing agreement without terminating the license), making it a small contributor to ALKS's overall revenue.
Patent expiry: Key patents have expired, opening the door to additional generic entrants beyond Lupin, which would further compress margins and volumes.

Upcoming Catalysts

  • No upcoming binary catalysts for Risperdal Consta specifically. The drug is already approved and faces generic erosion. For Alkermes overall, the key catalysts are quarterly earnings reports showing manufacturing/royalty revenue trends and the company's orexin pipeline readouts expected over the next year.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Alkermes plc. 8-K ALKS ·Originating report

Sources · 10

Hover a chip for the title
1 alkermes.com2 fintel.io3 lupin.com4 drugstorenews.com5 finsee.ai6 marketscreener.com7 accessdata.fda.gov8 investor.alkermes.com9 businesswire.com10 fool.com